Delegation of Authority, 60245-60246 [2020-21098]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 186 / Thursday, September 24, 2020 / Notices
60245
Appendix I: Statutory ~equirenient of Annual Report Components
This annual report, NQF20l 9Activltles: Report to Congre$S and.the Secretaryofthe.Deportment of
H.ealth and Numrin Servlces:1 highlightsand sui:nmarizes thewOl'k ttiat NQF perfurmed bet\YeenJ~nuary
land December 31, 20:tiu:ndet contrict with the u.s: Department ofHealth and Homal:i Servk:es (HHS}
in the following six areas:
•
•
•
•
•
•
Recommendations on the f\latronai Quality Strategy and Priorities;
Quality and Efficiency l\lleasorement tnitiatili:es (Perfurmance 1\/!easures);
Stakeholder ~mmendations on Quality and Effidem:y Measures;
Gaps.on EridotiiedQoality and Effidel'lcy Measutes across HHS Programs;
Gaps ln Evidence and Targeted Research Needs; and
Cootdination withMeasorementlnitiatives by Other Payers.
Congress has rec6gritl:ed the role of a "rooseoois based entity'' (CBE), cuirently NQF,. ln helpiogcto forge
agreement across the publlc and private.sectors about what to measure and improve in healthcare; The
200$ Medlt.:ire Improvement$ for P.itlents a1nf ProvldE!rs Act (MIPPA) (Pl 110-275) establisfled the
responsibllitiefofthe :eonsensus,ba~ entity by ereatiri~se:etionl800oftheSocial SetorityAct. The
2010PatientProte:etfon and Affordable Care Act (ACAl (Pl 111·148)modified and added to the
CQnsensus-based entity's respom;ibilitles. 'The American Taxpayer Relief A:etof 2012 (Pl 112-24o}
extended funding under the MlPPAstatute to the consensus-based entity through fiscal year 2013. The
Protecting Access to Medicare Ad of 2014 (Pl1f3-93} extendedfuoding under the MIPPAand ACA
statutes to the. ci:i11!iel'ii!OS0based entity through March 31, 2015:. ~on 207 of the lllledicare Ao:ess .and
Children's Health Insurance Program {CHIP} Reauthorizatioo Act of 2015 ·(MACRA) (Pl114-10J extended
funding undE!r sectjC1n 1890(d)(2) of the:Sodal Security .Act for qualify i:ne~sure endC>Bementjlnpu~, and
selection for fi$cill years..201SthroOgh 2017. Section 50200ofthe Bipartisan BOdget Act of2018
extended funding for federal quality efforts for.two years(October 2017- September 201~)amoog
other requirements. Bipartisan actlon·by numerous Congresses over several years has reinforced the
Importance of the role of the CBE. In a:CCOl'dance with section 1890 of:the Social Security Act, NQF, In its
designation as.the CBE; is chatgedto report annually.on its work to Congress and the HHS Secretary.
As.amended by the.above laws, the Social Security Act (theAct)-sfXldfttai/ysectfon 1890(b)(S)(A)mandatesthat the entity report to °"1gre$S and. the Secretary ofthe Deportment of Healthandfluman
Sei\lk:es (HHS) no later them Match 1st of each year.
The report must Jll(;fude descriptions of:
•
•
•
•
howNQF has implemented quality anclefficiem:y rti«lsurementirilti<ttives undetthe Act am:/
coordinated.these initiatives with Nloseimplemented by other payerst
NQf's recomme(l:datkmswith respect to.anlntegra.ted national strotegy amfprfotities fix
healthcare fXlrfarmam:e measurementin. all applicable settings;
NQPs pe,formance of the duties required underits amtractwith HHS IAppendix A};
gaps in endorsed quality.and efficiency measures; JncJuding measures that are within priority
at'eas identified by the ~cretaty under HHS' national strategy, ar,d wheN! quality and ejfit;iency
meo.sures areunavi:1ilabte. ot1Md¢4®teto.identW of address such gaps;
areas Jn which evident:e ls insufficient ta support ei'!!Jorsement ofmeasutesln priority ate(IS:
1Wntified by the National auality5ttategy,. <Ind wheht tatgetedteseardr mtrY addresuuch gaps;
[FR Doc. 2020–21103 Filed 9–23–20; 8:45 am]
BILLING CODE 4120–01–C
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Delegation of Authority
Notice is hereby given that I have
delegated to the Administrator, Health
Resources and Services Administration
(HRSA), or his or her successor, the
authorities that are vested in the
VerDate Sep<11>2014
17:00 Sep 23, 2020
Jkt 250001
PO 00000
Frm 00121
Fmt 4703
Sfmt 4703
Secretary of Health and Human Services
under sections 1833(bb) and 1834(o)(3)
of the Social Security Act (42 U.S.C.
1395l and 42 U.S.C. 1395m(o)(3),
respectively), as added by section 6083
of the Substance Use—Disorder
Prevention that Promotes Opioid
Recovery and Treatment (SUPPORT) for
Patients and Communities Act, Public
Law 115–271. This authorizes the HRSA
Administrator, on behalf of the
E:\FR\FM\24SEN1.SGM
24SEN1
EN24SE20.076</GPH>
•
60246
Federal Register / Vol. 85, No. 186 / Thursday, September 24, 2020 / Notices
Secretary, to pay Federally Qualified
Health Center and Rural Health Clinic
for the training costs of eligible
physicians and practitioners who obtain
Drug Addiction Treatment Act of 2000
waivers to furnish opioid use disorder
treatment services. This delegation may
not be redelegated and does not confer
authority to issue regulations.
This delegation of authorities is
effective upon date of signature.
Dated: September 18, 2020.
Alex M. Azar II,
Secretary, Department of Health and Human
Services.
[FR Doc. 2020–21098 Filed 9–23–20; 8:45 am]
BILLING CODE 4150–03–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of The Director, National
Institutes of Health; Cancellation of
Meeting
Notice is hereby given of the
cancellation of the Office of The
Director, National Institutes of Health,
October 9, 2020, 3:00 p.m. to October 9,
2020, 4:00 p.m., National Institutes of
Health, Building One, One Center Drive,
Bethesda, MD 20892 which was
published in the Federal Register on
August 26, 2020, 85 FR 52614.
This meeting is being cancelled due to
scheduling difficulties and the
presentation will be rescheduled for the
ACD in December 2020.
Dated: September 21, 2020.
Natasha M. Copeland,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–21118 Filed 9–23–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
VerDate Sep<11>2014
17:54 Sep 23, 2020
Jkt 250001
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Novel Synthetic Nucleic Acid
Technology Development SEP.
Date: December 7, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 300, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 300, Bethesda, MD 20892, 301–594–
4280, mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: September 21, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–21091 Filed 9–23–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Initial Review
Group; Genome Research Review Committee.
Date: November 5–6, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 300, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
PO 00000
Frm 00122
Fmt 4703
Sfmt 4703
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 300, Bethesda, MD 20892, 301–594–
4280, mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: September 21, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–21089 Filed 9–23–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Musculoskeletal, Oral
and Skin Sciences Integrated Review Group;
Skeletal Biology Structure and Regeneration
Study Section.
Date: October 22–23, 2020.
Time: 9:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Yanming Bi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214,
MSC 7814, Bethesda, MD 20892, 301–451–
0996, ybi@csr.nih.gov.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Imaging Probes and
Contrast Agents Study Section.
Date: October 22–23, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Donald Scott Wright,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 85, Number 186 (Thursday, September 24, 2020)]
[Notices]
[Pages 60245-60246]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21098]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Delegation of Authority
Notice is hereby given that I have delegated to the Administrator,
Health Resources and Services Administration (HRSA), or his or her
successor, the authorities that are vested in the Secretary of Health
and Human Services under sections 1833(bb) and 1834(o)(3) of the Social
Security Act (42 U.S.C. 1395l and 42 U.S.C. 1395m(o)(3), respectively),
as added by section 6083 of the Substance Use--Disorder Prevention that
Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and
Communities Act, Public Law 115-271. This authorizes the HRSA
Administrator, on behalf of the
[[Page 60246]]
Secretary, to pay Federally Qualified Health Center and Rural Health
Clinic for the training costs of eligible physicians and practitioners
who obtain Drug Addiction Treatment Act of 2000 waivers to furnish
opioid use disorder treatment services. This delegation may not be
redelegated and does not confer authority to issue regulations.
This delegation of authorities is effective upon date of signature.
Dated: September 18, 2020.
Alex M. Azar II,
Secretary, Department of Health and Human Services.
[FR Doc. 2020-21098 Filed 9-23-20; 8:45 am]
BILLING CODE 4150-03-P
